United States: Healthcare Law Update: October 2019

Regulation

FDA Guidance on Patient Engagement in Medical Device Development

Shannon B. Hartsfield

In recent years, the healthcare industry has been turning greater attention to the need to engage or involve patients in developing new technologies and systems to improve healthcare delivery. These patient engagement initiatives are sometimes referred to as patient "activation," shared decision-making or, in the words of the Institute for Healthcare Improvement, "actions that people take for their health and to benefit from care."

The U.S. Food and Drug Administration (FDA) first began including patient perspectives in its FDA Advisory Committee meetings in 1991. Subsequently, the FDA, along with the Clinical Trials Transformation Initiative, established the Patient Engagement Collaborative. The collaborative, facilitated by the 21st Century Cures Act and the Food and Drug Administration Reauthorization Act, is modeled on the European Medicines Agency Patients' and Consumers Working Party. The collaborative provides "an ongoing forum to discuss how to achieve more meaningful patient engagement in medical product development and other regulatory discussions." The FDA launched the Patient Engagement Advisory Committee (PEAC) in 2017. In 2018, the FDA established a pilot program called the Patient and Caregiver Connection to enable the FDA to obtain input from patients and patient organizations when evaluating medical device submissions.

The FDA's patient engagement efforts are continuing. In September 2019, the FDA announced the issuance of draft, nonbinding recommendations entitled "Patient Engagement in the Design and Conduct of Medical Device Clinical Investigations." The draft guidance is a result of the first PEAC meeting. Dr. Norman "Ned" Sharpless, Acting Commissioner of Food and Drugs for FDA, issued a statement indicating that the FDA is "committed to keeping patients, their families and caregivers at the center of our work and to deepening their involvement in how we review medical device applications." He noted that, "[t]ypically, medical device developers work with health care providers, clinical researchers and the FDA to design and test medical devices to understand how the product will benefit patients, but the process often does not incorporate direct input from patients." The FDA recognizes, however, that it can be a challenge to get patients to participate in clinical trials.

The draft guidance defines "patient engagement" as "intentional, meaningful interactions with patients that provide opportunities for mutual learning, and effective collaborations." Dr. Sharpless observed that, "[w]hen we work with patients early-on, we can advance the development and evaluation of innovative medical devices." The draft guidance includes FDA's recommendations for how manufacturers might "engage patients in multiple aspects of medical device clinical investigation design." The draft guidance, which does not establish legally enforceable responsibilities, is meant to accomplish a number of objectives, including:

  • helping clinical investigation sponsors understand how they can use patient engagement to obtain relevant information to improve the design and conduct of medical device clinical investigations
  • demonstrating the benefits of engaging patients early in the process of developing a medical device
  • showing which patient engagement activities will generally not be considered to be "research" subject to institutional review board (IRB) requirements
  • addressing common questions about collecting and providing patient engagement information to the FDA

The FDA has solicited comments on the draft guidance. Those comments are due on Nov. 25, 2019 and instructions for submitting them were published at 84 Federal Register 50047 on Sept. 24, 2019.

False Advertising

Competitive Harms Necessary for Lanham Act Standing

Nathan A. Adams IV

In ThemoLife Int'l LLC v. Am. Fitness Wholesalers LLC, No. CV-18-04189, 2019 WL 3840988 (D. Ariz. Aug. 15, 2019), the court granted the defendant's motion to dismiss the plaintiff's Lanham Act claims for lack of standing. The plaintiff alleged that the defendant is unfairly competing in the dietary supplement market through false advertising of products labeled as dietary supplements that contain ingredients the FDA labels as "drugs." The plaintiff alleged that 142 products advertised on the defendant's website contain such ingredients without any disclosure of the nature of the ingredients as "drugs." The court dismissed the complaint because the plaintiff competes higher up the supply chain than the defendant by marketing to production companies who use its patented ingredients and technology to manufacture dietary supplements. The defendant sells and advertises dietary supplements manufactured by third parties.

To establish Article III injury in a false advertising suit, the plaintiff must show that consumers who bought the defendant's product under a mistaken belief fostered by the defendant would have otherwise bought the plaintiff's product. A commercial or competitive injury is usually presumed under the Lanham Act when the defendant and plaintiffs are direct competitors. When companies are not direct competitors, competitive injuries may be shown when companies are involved in the same market if that involvement puts them within the "zone of interest" of the Lanham Act. The plaintiff's failure to allege competitive injuries such as how its sales or reputation were adversely affected also undermined its Lanham Act claims.

Privacy

No Attorney-Client Privilege for Hospital Lawyer's Communications with ER Doctor

Charles A. Weiss

Communications between a lawyer and a client, in confidence, for the purpose of obtaining or providing legal advice are ordinarily protected by attorney-client privilege. In the case of corporate or organizational clients such as hospitals, the issue of "who is the client" can be complicated. Different kinds of legal relationships exist between a hospital and its medical staff, including regular full-time employment of physicians by the hospital, an independent contractor relationship, the classic voluntary medical staff model and employment of the physicians by a group that itself contracts with the hospital to provide medical staff.

In Hermanson v. Multi-Care Health System, Inc., 448 P.3d 153 (Wash. App. 2019), a patient treated in the emergency department of Tacoma General Hospital for injuries sustained in a car crash sued the hospital for disclosing to the police the results of his blood-alcohol test. His claim was based on a breach of confidentiality, not a claim that his actual medical care was deficient. The treating physician was an employee of a regional nonprofit entity (called the Trauma Trust), organized by several hospitals to improve and coordinate trauma care in the Tacoma, Washington area. Although neither the physician nor Trauma Trust were named as defendants in the lawsuit, they retained the same attorney who was defending the hospital.

At issue was whether the hospital's lawyer could interview the physician in private to collect facts pertinent to the hospital's defense and whether attorney-client privilege would protect their conversations. The plaintiff objected, asserting that such conversations would breach the physician's duty of confidentiality to him as well as a Washington rule that prohibits attorneys from speaking with a plaintiff/patient's treating physician without consent by the patient.

The hospital responded that this case fell within an exception to the no-contact rule invoked by the plaintiff. Specifically, that rule did not apply when the treating physician was also an employee of the defendant hospital. In that circumstance, because the treating physician was also an employee of the lawyer's client, the no-contact rule gave way to a different rule governing representation by lawyers of corporate or organizational clients that recognizes that such clients can act only through humans (who are typically their employees).

The Washington court rejected the hospital's argument based on the fact that the physician was not an employee of the defendant hospital. It recognized that some courts have ruled that non-employee agents of a corporate or organization client with responsibilities that make them functionally indistinguishable from employees will be treated as employees for purposes of the attorney-client privilege, but declined to follow those cases in favor of a narrow approach under which the fact that the physician was not an employee of the hospital was dispositive against the application of privilege.

The nuances and application of the attorney-client privilege vary from state to state, but this case illustrates one potentially unexpected result when members of the medical staff are not employees of the hospital: communications between the hospital's attorneys and members of the medical staff may not be privileged, even when, as here, their purpose is to defend the hospital.

Enforcement

Dismissal of AKS and Stark Claims Against HCA Affirmed

Nathan A. Adams IV

In Bingham v. HCA, Inc., No. 16-17059, 2019 WL 3451045 (11th Cir. July 31, 2019), the court of appeals affirmed the district court's grant of summary judgment in favor of the defendant on relator's qui tam action under the False Claims Act for violation of the Anti-Kickback Statute (AKS) and Stark Statute. HCA hired Tegra Independence Medical Surgical, L.C. to develop a medical office building in Independence, Missouri. As part of the development project, Tegra leased out space in the building to physicians. The relator alleged that HCA paid Tegra $4 million in improper subsidies through an initial lease and an arrangement involving parking facilities at the building, which Tegra passed on to physician tenants through payments under cash flow participation agreements, low initial lease rates, restricted use waivers and free office improvements. In exchange, the relator alleged HCA received $260 million in Medicare and Medicaid payments from patients referred to HCA's hospital by the physician tenants. The relator alleged that HCA was involved in a similar arrangement with a developer and physicians in Aventura, Florida.

The district court concluded that the supposed "low-end" rents were within the range of market rates for new construction. About the alleged free improvements, the court determined that the relator failed to tie them to specific physician tenants who were or could be referral sources or present evidence that the use waivers were anything other than a standard exercise of discretion under the relevant leases or that HCA was required to ask for something in exchange for the use waivers. Therefore, the court of appeals affirmed summary judgment on the plaintiff's AKS claim.

Likewise, the court of appeals agreed that there is no genuine factual dispute over whether a prohibited indirect compensation arrangement under the Stark Law exists inasmuch as HCA showed that there was no correlation between the size of physician tenants' space leases and their referrals to HCA. The court of appeals also affirmed the district court's decision to dismiss the relator's second amended complaint because the relator impermissibly used information learned through discovery to supplement allegations, and without this additional information the complaint would not have met the heightened pleading standard of Federal Rule of Civil Procedure 9(b).

Criminal Conviction Under AKS Affirmed for Patient Referral Payments

Nathan A. Adams IV

In United States v. Crane, No. 17-20776, 2019 WL 3072148 (5th Cir. July 12, 2019), the court of appeals affirmed the defendant's conviction for conspiring to violate the AKS. The defendant worked as a patient recruiter, van driver and psychiatric technician for Devotions Care Solutions, a partial hospitalization program providing intensive outpatient treatment for patients suffering an "acute exacerbation" of a chronic mental illness. In an interview with the Federal Bureau of Investigation (FBI), the defendant admitted that he was paid for patient referrals and that he knew the payments were wrong but he needed the money. The defendant argued that the evidence at trial was insufficient to support his conviction, but the court disagreed. The government corroborated his testimony with independent evidence such as a coworkers' testimony and the marketer's list identifying the patients that each recruiter brought in.

Medicare

FFY 2014 Merged Hospital Policy Subject to APA Review

Nathan A. Adams IV

In Yale New Haven Hosp. v. Azar, No. 3:18-cv-1230, 2019 WL 3387041 (D. Conn. July 25, 2019), the court ruled that it has jurisdiction to decide whether the secretary of the U.S. Department of Health and Human Service's promulgation of the Federal Fiscal Year (FFY) 2014 Merged Hospital Policy outside of the requirements of notice and comment of the Medicare Act and Administrative Procedure Act (APA) was unlawful, but lacked jurisdiction over the balance of the plaintiff's claims due to the preclusion statute contained in the Patient Protection and Affordable Care Act (ACA), codified at Section 1395ww(r)(3) of Title 42 of the United States Code.

The plaintiff merged with another hospital effective Sept. 12, 2012. As a result of the transaction, the plaintiff assumed the other hospital's Medicare provider agreement and its Centers for Medicare & Medicaid Services (CMS) certification number was subsumed under that of the plaintiff's. Under the policy, CMS excluded the inpatient days from the acquired hospital when calculating the plaintiff's FFY 2014 Uncompensated Care (UC) Disproportionate Share Hospital (DSH) payment. As a result, the plaintiff sued for violation of the APA and Medicare Act and on the grounds the payment was unsupported by substantial evidence in the record and ultra vires and for a writ of mandamus, under the All Writs Act, and in violation of the Constitution.

The court determined that the plaintiff failed to state a constitutional claim and that the court could not review the data that underlies the secretary's estimate because it would eviscerate the bar on judicial review, as would mandamus or another writ. In contrast, the challenge to the promulgation of the policy itself was not to the secretary's estimate of the plaintiff's DSH payment, any underlying data or the secretary's choice of such data; instead, it is a challenge to the procedure by which the secretary established the policy. Congress cast a wide net in precluding judicial review of any estimate of UC DSH payments, but "was equally clear in requiring that the Secretary adhere to notice-and-comment rulemaking in promulgating regulations."

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Topics
 
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions